CYP3A5 (Cytochrome P450 3A5) variants and mutations
CYP3A5 (also known as Cytochrome P450 3A5) is a human protein-coding gene encoding a cytochrome P450 3A5 protein. It contributes to CYP3A-mediated drug metabolism in individuals who express functional enzyme, with large genotype-dependent differences in abundance. CYP3A5 genotype is particularly important for tacrolimus clearance and dose requirements. This analysis covers 785 CYP3A5 variants and mutations. Of these, 18% have clinical classifications, 79% have computational variant effect predictions from REVEL, and 67% have population-specific frequency data. Disease context includes HIV infectious disease, HIV-1 infection, and hepatitis C virus infection. Example CYP3A5 variants include L3I, P5Q, and L7S.
Variant analysis overview
- Gene: CYP3A5
- Protein: Cytochrome P450 3A5
- UniProt accession: P20815
- Organism: Homo sapiens
- Variants analyzed: 785
- Variant scope: all variants
- Completed: 2026-08-10
Variant and mutation evidence
- Variant composition: 531 unspecified-consequence records; 5 stop lost; 88 synonymous variants; 119 missense variants; 23 frameshift variants; 8 stop-gained variants; 3 splice-region variants; 4 in-frame deletions; 1 in-frame insertions; 3 substitution
- Clinical classifications: 9 benign or likely benign; 39 uncertain-significance; 94 other clinical labels.
- Computational signals: 64 REVEL high-risk.
- Variant classes: 629 missense; 88 synonymous; 62 truncating or splice.
- Prediction scores: 621 variants have prediction scores (80% of the analyzed set).
- Literature: 9 publications are represented in the literature summary.
Clinical, disease, and population context
- Clinical annotations: 146 variants have clinical annotations.
- Population evidence: 615 variants have population-frequency evidence.
- Disease context: 25 disease associations are represented. Top associations: HIV infectious disease, HIV-1 infection, hepatitis C virus infection, chronic hepatitis C virus infection, infection, COVID-19, Cirrhosis, viral infectious disease, hepatitis B virus infection, tuberculosis, malaria, hepatitis D virus infection.
Protein structure and variant hotspots
- Protein features: 1 binding sites.
- Ancestry evidence: 526 variants have ancestry-specific frequency data.
- 3D hotspots: 2 hotspot clusters were identified. Clusters at residues 343-453 (tolerant, 14 variants); residues 371-432 (tolerant, 12 variants).
- Allosteric analysis: 1 functional sites were identified.
- gnomAD gene constraint: pLI 0.00 (tolerant of loss-of-function variation); LOEUF 0.91; missense Z-score 1.11.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CYP3A5 variants
Examples include L3I, P5Q, L7S, A8V, V9E, V9L, E10K, W12*. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- L3I (p.Leu3Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P5Q (p.Pro5Gln), gnomAD rs1264426886, REVEL 0.11, CADD 17.20
- L7S (p.Leu7Ser), gnomAD rs1487619260, REVEL 0.05, CADD 22.50, Uncertain significance, not specified
- A8V (p.Ala8Val), rs369170873, ClinGen CA4368833, cosmic curated COSV10455, ClinVar RCV004300145, REVEL 0.04, CADD 19.70, Uncertain significance, not specified
- V9E (p.Val9Glu), gnomAD rs1321809365
- V9L (p.Val9Leu), ExAC rs748910360, gnomAD rs748910360
- E10K (p.Glu10Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- W12* (p.Trp12Ter), TOPMed rs1288443539, gnomAD rs1288443539, CADD 34.00
- L14I (p.Leu14Ile), NCI-TCGA Cosmic COSV5612, cosmic curated COSV56121, Variant assessed as somatic; moderate impact.
- L15R (p.Leu15Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y23* (p.Tyr23Ter), ExAC rs777442533, gnomAD rs777442533
- Y23C (p.Tyr23Cys), cosmic curated COSV56121, TOPMed rs1812667577, gnomAD rs1812667577, REVEL 0.21, CADD 26.00
- Y25H (p.Tyr25His), cosmic curated COSV56119, Ensembl rs1427321425
- T27A (p.Thr27Ala), Ensembl rs2151459200
- T27N (p.Thr27Asn), TOPMed rs1330633182, REVEL 0.02, CADD 10.90
- R28C (p.Arg28Cys), rs55817950, cosmic curated COSV56124, UniProt VAR 024731, ExAC rs55817950, REVEL 0.07, CADD 13.30, Benign, in allele CYP3A5*8
- R28H (p.Arg28His), rs769315225, NCI-TCGA Cosmic COSV5611, cosmic curated COSV56119, ExAC rs769315225, REVEL 0.01, CADD 0.49, Variant assessed as somatic; moderate impact., in allele CYP3A5*8
- R28P (p.Arg28Pro), ExAC rs769315225, TOPMed rs769315225, gnomAD rs769315225
- T29I (p.Thr29Ile), rs1401028894, NCI-TCGA Cosmic COSV9976, cosmic curated COSV99769, gnomAD rs1401028894, REVEL 0.08, CADD 15.00, Variant assessed as somatic; moderate impact.
- H30Y (p.His30Tyr), rs28383468, ClinGen CA4368761, ClinVar RCV003433969, UniProt VAR 024728, REVEL 0.07, CADD 2.40, Likely benign, not provided
- F33L (p.Phe33Leu), NCI-TCGA TCGA novel, REVEL 0.08, CADD 19.00, Variant assessed as somatic; high impact.
- F33S (p.Phe33Ser), rs867453902, NCI-TCGA Cosmic COSV5611, Ensembl rs867453902, AlphaMissense 0.96, MetaLR 0.13, Variant assessed as somatic; moderate impact.
- K34R (p.Lys34Arg), NCI-TCGA Cosmic COSV5612, cosmic curated COSV56122, Variant assessed as somatic; moderate impact.
- L36R (p.Leu36Arg), ExAC rs776441407, gnomAD rs776441407, REVEL 0.21, CADD 13.50
- I38V (p.Ile38Val), rs200980665, NCI-TCGA Cosmic COSV5611, cosmic curated COSV56118, 1000Genomes rs200980665, AlphaMissense 0.19, MetaLR 0.02, Variant assessed as somatic; moderate impact.
- P39S (p.Pro39Ser), NCI-TCGA Cosmic COSV5612, cosmic curated COSV56122, Variant assessed as somatic; moderate impact.
- P41R (p.Pro41Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T42I (p.Thr42Ile), rs1374335261, TOPMed rs1374335261, gnomAD rs1374335261, REVEL 0.03, CADD 2.73, Variant assessed as somatic; moderate impact.
- P43H (p.Pro43His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P43L (p.Pro43Leu), TOPMed rs1460641728, gnomAD rs1460641728, REVEL 0.32, CADD 22.90
- L46F (p.Leu46Phe), rs150999943, ClinGen CA4368757, ClinVar RCV004267788, ESP rs150999943, REVEL 0.13, CADD 0.00, Likely benign, not specified
- L46M (p.Leu46Met), ExAC rs748355697, TOPMed rs748355697, gnomAD rs748355697, REVEL 0.19, CADD 22.70
- V50I (p.Val50Ile), 1000Genomes rs80026734, ExAC rs80026734, REVEL 0.01, CADD 0.00
- L51F (p.Leu51Phe), gnomAD rs1377271967, REVEL 0.09, CADD 9.90
- S52F (p.Ser52Phe), rs930419944, NCI-TCGA Cosmic COSV9976, cosmic curated COSV99769, gnomAD rs930419944, REVEL 0.03, CADD 0.05, Variant assessed as somatic; moderate impact.
- Y53C (p.Tyr53Cys), ExAC rs72552791, TOPMed rs72552791, gnomAD rs72552791, REVEL 0.48, CADD 22.80
- Y53H (p.Tyr53His), rs1241244504, ClinGen CA368368947, ClinVar RCV004164318, TOPMed rs1241244504, REVEL 0.46, CADD 22.80, Uncertain significance, not specified
- R54C (p.Arg54Cys), 1000Genomes rs566629410, ExAC rs566629410, TOPMed rs566629410, gnomAD rs566629410, REVEL 0.08, CADD 22.90
- R54G (p.Arg54Gly), 1000Genomes rs566629410, ExAC rs566629410, TOPMed rs566629410, gnomAD rs566629410, REVEL 0.07, CADD 16.60
- R54H (p.Arg54His), 1000Genomes rs186648988, ExAC rs186648988, TOPMed rs186648988, gnomAD rs186648988, REVEL 0.04, CADD 8.54
- R54S (p.Arg54Ser), 1000Genomes rs566629410, ExAC rs566629410, TOPMed rs566629410, gnomAD rs566629410, REVEL 0.03, CADD 14.50
- Q55* (p.Gln55Ter), cosmic curated COSV56120, gnomAD rs1213117276
- G56C (p.Gly56Cys), gnomAD rs1463517926, REVEL 0.52, CADD 27.20
- G56D (p.Gly56Asp), ESP rs367849047, ExAC rs367849047, TOPMed rs367849047, gnomAD rs367849047, REVEL 0.50, CADD 23.60
- W58* (p.Trp58Ter), NCI-TCGA Cosmic COSV5611, cosmic curated COSV56118, CADD 27.70, Variant assessed as somatic; high impact.
- W58S (p.Trp58Ser), gnomAD rs1303343223, REVEL 0.15, CADD 8.42
- K59T (p.Lys59Thr), rs749438221, ExAC rs749438221, gnomAD rs749438221, REVEL 0.09, CADD 2.48, Variant assessed as somatic; moderate impact.
- F60C (p.Phe60Cys), rs1368152429, NCI-TCGA Cosmic COSV5612, cosmic curated COSV56122, TOPMed rs1368152429, REVEL 0.24, CADD 23.00, Variant assessed as somatic; moderate impact.
- D61E (p.Asp61Glu), TOPMed rs1332786109, gnomAD rs1332786109, REVEL 0.36, CADD 3.83
- D61G (p.Asp61Gly), Ensembl rs1812033177, REVEL 0.42, CADD 23.80
- E63K (p.Glu63Lys), NCI-TCGA Cosmic COSV5611, cosmic curated COSV56118, NCI-TCGA Cosmic COSV9976, Variant assessed as somatic; moderate impact.
- C64F (p.Cys64Phe), TOPMed rs1338537223
- C64S (p.Cys64Ser), TOPMed rs1351082663, gnomAD rs1351082663, REVEL 0.34, CADD 18.40
- K67Q (p.Lys67Gln), Ensembl rs1812031933
- K67R (p.Lys67Arg), ExAC rs777815672, gnomAD rs777815672, REVEL 0.46, CADD 28.00
- Y68* (p.Tyr68Ter), TOPMed rs1271163092, gnomAD rs1271163092, CADD 35.00
- K70N (p.Lys70Asn), TOPMed rs1812030853, NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- W72* (p.Trp72Ter), TOPMed rs895150745, gnomAD rs895150745, CADD 35.00
- G73* (p.Gly73Ter), ExAC rs781230602, TOPMed rs781230602, gnomAD rs781230602, CADD 33.00
- G73R (p.Gly73Arg), NCI-TCGA TCGA novel, ExAC rs781230602, TOPMed rs781230602, gnomAD rs781230602, REVEL 0.30, CADD 22.70, Variant assessed as somatic; moderate impact.
- T74K (p.Thr74Lys), TOPMed rs1257327336, gnomAD rs1257327336, REVEL 0.27, CADD 21.10
- T74M (p.Thr74Met), TOPMed rs1257327336, gnomAD rs1257327336, REVEL 0.17, CADD 15.20
- E76D (p.Glu76Asp), Ensembl rs2151444826, REVEL 0.10, CADD 0.09
- G77A (p.Gly77Ala), gnomAD rs1489578513, REVEL 0.59, CADD 17.40
- Q78* (p.Gln78Ter), TOPMed rs1811786407, gnomAD rs1811786407, CADD 33.00
- P80R (p.Pro80Arg), TOPMed rs1263327720, gnomAD rs1263327720, REVEL 0.59, CADD 22.80
- V81A (p.Val81Ala), TOPMed rs1811784810
- L82M (p.Leu82Met), NCI-TCGA Cosmic COSV5612, cosmic curated COSV56123, Variant assessed as somatic; moderate impact.
- L82R (p.Leu82Arg), ESP rs56244447, ExAC rs56244447, TOPMed rs56244447, gnomAD rs56244447, REVEL 0.56, CADD 23.40
- L82V (p.Leu82Val), ExAC rs745739575, TOPMed rs745739575, gnomAD rs745739575, REVEL 0.17, CADD 6.93
- T85R (p.Thr85Arg), TOPMed rs981228083, gnomAD rs981228083, REVEL 0.28, CADD 13.70
- P87T (p.Pro87Thr), gnomAD rs1811782880, REVEL 0.45, CADD 18.10
- D88E (p.Asp88Glu), 1000Genomes rs201165536, ESP rs201165536, ExAC rs201165536, TOPMed rs201165536, REVEL 0.12, CADD 0.26
- D88H (p.Asp88His), ExAC rs753861581, TOPMed rs753861581, gnomAD rs753861581
- D88N (p.Asp88Asn), rs753861581, NCI-TCGA Cosmic COSV5612, cosmic curated COSV56120, ExAC rs753861581, REVEL 0.27, CADD 13.30, Variant assessed as somatic; moderate impact.
- V89M (p.Val89Met), cosmic curated COSV56118, ExAC rs755699295, TOPMed rs755699295, gnomAD rs755699295, REVEL 0.11, CADD 12.90
- R91K (p.Arg91Lys), ExAC rs767268743, gnomAD rs767268743, REVEL 0.14, CADD 10.20
- V93L (p.Val93Leu), rs759099183, ClinGen CA4368701, ClinVar RCV004099798, ExAC rs759099183, REVEL 0.42, CADD 14.00, Uncertain significance, not specified
- L94Q (p.Leu94Gln), ExAC rs752003788, TOPMed rs752003788, gnomAD rs752003788, REVEL 0.73, CADD 23.70
- E97* (p.Glu97Ter), ExAC rs763263522, TOPMed rs763263522, gnomAD rs763263522, CADD 37.00
- E97G (p.Glu97Gly), Ensembl rs1811779753
- C98S (p.Cys98Ser), NCI-TCGA Cosmic COSV9976, cosmic curated COSV99769, Variant assessed as somatic; moderate impact.
- S100C (p.Ser100Cys), 1000Genomes rs41279857, ESP rs41279857, ExAC rs41279857, TOPMed rs41279857, REVEL 0.36, CADD 23.20, Likely benign
- S100Y (p.Ser100Tyr), rs41279857, ClinGen CA4368696, ClinVar RCV003906985, 1000Genomes rs41279857, REVEL 0.34, CADD 23.20, Likely benign, CYP3A5-related disorder
- T103I (p.Thr103Ile), ExAC rs761882111, TOPMed rs761882111, gnomAD rs761882111, REVEL 0.68, CADD 25.20
- T103K (p.Thr103Lys), ExAC rs761882111, TOPMed rs761882111, gnomAD rs761882111, REVEL 0.61, CADD 25.40
- N104I (p.Asn104Ile), TOPMed rs1186517408, gnomAD rs1186517408, REVEL 0.59, CADD 25.20
- R105* (p.Arg105Ter), rs776567184, ExAC rs776567184, gnomAD rs776567184, CADD 34.00, Variant assessed as somatic; high impact.
- R105G (p.Arg105Gly), ExAC rs776567184, gnomAD rs776567184, REVEL 0.44, CADD 23.00
- R105Q (p.Arg105Gln), ExAC rs768977839, TOPMed rs768977839, gnomAD rs768977839, REVEL 0.43, CADD 23.30
- R106S (p.Arg106Ser), TOPMed rs945906053, gnomAD rs945906053
- S107=, NCI-TCGA Cosmic COSV5611, Variant assessed as somatic; low impact.
- S107P (p.Ser107Pro), gnomAD rs1278132844, REVEL 0.16, CADD 0.00
- V111G (p.Val111Gly), Ensembl rs1811094527
- G112V (p.Gly112Val), ExAC rs748003177, gnomAD rs748003177, REVEL 0.39, CADD 22.10
- M114V (p.Met114Val), TOPMed rs1488049313, gnomAD rs1488049313, REVEL 0.11, CADD 16.40
- S116T (p.Ser116Thr), Ensembl rs200208768, REVEL 0.14, CADD 2.07
- A117T (p.Ala117Thr), Ensembl rs1811093404, REVEL 0.22, CADD 20.60
- I118T (p.Ile118Thr), gnomAD rs1811093184, REVEL 0.51, CADD 23.60
- L120S (p.Leu120Ser), rs199866223, ClinGen CA163145269, ClinVar RCV004125023, gnomAD rs199866223, REVEL 0.11, CADD 9.15, Uncertain significance, not specified
- E122V (p.Glu122Val), NCI-TCGA Cosmic COSV9976, Variant assessed as somatic; moderate impact.
- D123E (p.Asp123Glu), ExAC rs746469422, gnomAD rs746469422, REVEL 0.43, CADD 23.80
- D123V (p.Asp123Val), Ensembl rs1335132254
- E124D (p.Glu124Asp), ExAC rs779681386, TOPMed rs779681386, REVEL 0.07, CADD 5.99
- E124G (p.Glu124Gly), gnomAD rs1811091470, REVEL 0.45, CADD 23.60
- E124K (p.Glu124Lys), Ensembl rs1811092009
- E125K (p.Glu125Lys), NCI-TCGA Cosmic COSV5611, Variant assessed as somatic; moderate impact.
- W126R (p.Trp126Arg), gnomAD rs1294331881, REVEL 0.81, CADD 26.50
- K127N (p.Lys127Asn), NCI-TCGA Cosmic COSV5612, Variant assessed as somatic; moderate impact.
- K127R (p.Lys127Arg), TOPMed rs1255610231, gnomAD rs1255610231, REVEL 0.19, CADD 22.00
- R128K (p.Arg128Lys), NCI-TCGA Cosmic COSV5612, NCI-TCGA Cosmic COSV9977, Variant assessed as somatic; moderate impact.
- R128S (p.Arg128Ser), Ensembl rs1811090553
- I129T (p.Ile129Thr), TOPMed rs1438984552
- R130Q (p.Arg130Gln), ExAC rs758037875, TOPMed rs758037875, gnomAD rs758037875, REVEL 0.80, CADD 24.90
- R130W (p.Arg130Trp), TOPMed rs1811090111, REVEL 0.70, CADD 23.60
- S131* (p.Ser131Ter), NCI-TCGA Cosmic COSV5612, CADD 33.00, Variant assessed as somatic; high impact.
- L132V (p.Leu132Val), 1000Genomes rs189107290, ExAC rs189107290, TOPMed rs189107290, gnomAD rs189107290, REVEL 0.10, CADD 1.03
- L133P (p.Leu133Pro), TOPMed rs1383200930, gnomAD rs1383200930, REVEL 0.80, CADD 26.50
- T136A (p.Thr136Ala), gnomAD rs1451231918, REVEL 0.13, CADD 8.87
- T136N (p.Thr136Asn), 1000Genomes rs539204136, ExAC rs539204136, TOPMed rs539204136, gnomAD rs539204136, REVEL 0.23, CADD 14.50
- T138S (p.Thr138Ser), Ensembl rs994206644
- G140* (p.Gly140Ter), ExAC rs764608096, TOPMed rs764608096, gnomAD rs764608096, Uncertain significance
- G140R (p.Gly140Arg), ExAC rs764608096, TOPMed rs764608096, gnomAD rs764608096, REVEL 0.58, CADD 23.20, Uncertain significance, not specified
- K141T (p.Lys141Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K143R (p.Lys143Arg), ESP rs367673189, ExAC rs367673189, TOPMed rs367673189, gnomAD rs367673189, REVEL 0.35, CADD 25.30
- E144G (p.Glu144Gly), ExAC rs767910505, gnomAD rs767910505, REVEL 0.52, CADD 34.00
- E144K (p.Glu144Lys), ESP rs144541701, TOPMed rs144541701, gnomAD rs144541701, REVEL 0.30, CADD 24.10
- M145I (p.Met145Ile), TOPMed rs1811056679
- M145T (p.Met145Thr), ExAC rs764576184, TOPMed rs764576184, gnomAD rs764576184, REVEL 0.57, CADD 24.60
- M145V (p.Met145Val), gnomAD rs1811057464, REVEL 0.48, CADD 22.80
- F146L (p.Phe146Leu), gnomAD rs1237059482, REVEL 0.14, CADD 19.00
- P147S (p.Pro147Ser), Ensembl rs1811055949
- I148M (p.Ile148Met), TOPMed rs1303487578, gnomAD rs1303487578, REVEL 0.28, CADD 21.00
- I148N (p.Ile148Asn), ESP rs375534267, ExAC rs375534267, TOPMed rs375534267, gnomAD rs375534267, REVEL 0.66, CADD 25.70
- I148T (p.Ile148Thr), ESP rs375534267, ExAC rs375534267, TOPMed rs375534267, gnomAD rs375534267, REVEL 0.29, CADD 23.40
- I149T (p.Ile149Thr), 1000Genomes rs142823108, ESP rs142823108, ExAC rs142823108, TOPMed rs142823108, REVEL 0.72, CADD 24.70
- I149V (p.Ile149Val), 1000Genomes rs200965456
- A150D (p.Ala150Asp), gnomAD rs1391791047
- A150S (p.Ala150Ser), 1000Genomes rs201847489
- Q151L (p.Gln151Leu), 1000Genomes rs199858062, TOPMed rs199858062, gnomAD rs199858062, REVEL 0.35, CADD 18.40
- Q151R (p.Gln151Arg), 1000Genomes rs199858062, TOPMed rs199858062, gnomAD rs199858062
- Y152* (p.Tyr152Ter), 1000Genomes rs561555514, ExAC rs561555514, TOPMed rs561555514, gnomAD rs561555514, CADD 36.00
- Y152H (p.Tyr152His), rs752110760, ClinGen CA4368633, ClinVar RCV004370474, ExAC rs752110760, REVEL 0.13, CADD 18.10, Uncertain significance, not specified
- G153E (p.Gly153Glu), NCI-TCGA Cosmic COSV5612, Variant assessed as somatic; moderate impact.
- D154N (p.Asp154Asn), TOPMed rs967022729, gnomAD rs967022729, REVEL 0.23, CADD 22.00
- V157M (p.Val157Met), NCI-TCGA Cosmic COSV5612, Variant assessed as somatic; moderate impact.
- R158G (p.Arg158Gly), Ensembl rs1811052127, REVEL 0.13, CADD 23.00
- R158I (p.Arg158Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N159H (p.Asn159His), rs761517345, NCI-TCGA Cosmic COSV5611, ExAC rs761517345, gnomAD rs761517345, REVEL 0.16, CADD 21.80, Variant assessed as somatic; moderate impact.
- L160W (p.Leu160Trp), TOPMed rs1027101735, REVEL 0.55, CADD 26.10
- R161G (p.Arg161Gly), 1000Genomes rs200764640, ExAC rs200764640, gnomAD rs200764640, REVEL 0.09, CADD 22.70
- R162Q (p.Arg162Gln), ExAC rs760580189, gnomAD rs760580189, REVEL 0.04, CADD 14.00
- R162W (p.Arg162Trp), rs768530577, NCI-TCGA Cosmic COSV9977, ExAC rs768530577, TOPMed rs768530577, REVEL 0.23, CADD 24.50, Variant assessed as somatic; moderate impact.
- E163K (p.Glu163Lys), TOPMed rs1811049839, gnomAD rs1811049839, REVEL 0.04, CADD 6.35
- A164T (p.Ala164Thr), NCI-TCGA TCGA novel, Ensembl rs1811049571, Variant assessed as somatic; moderate impact.
- A164V (p.Ala164Val), TOPMed rs1271319389, gnomAD rs1271319389, REVEL 0.07, CADD 13.90, Uncertain significance, not specified
- E165G (p.Glu165Gly), gnomAD rs1213716478, REVEL 0.12, CADD 22.60
- E165Q (p.Glu165Gln), Ensembl rs1021575380
- K166* (p.Lys166Ter), TOPMed rs1209004470, gnomAD rs1209004470, CADD 34.00
- K166N (p.Lys166Asn), TOPMed rs1349204736, gnomAD rs1349204736, REVEL 0.10, CADD 8.76
- K168E (p.Lys168Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K168R (p.Lys168Arg), ExAC rs771596018, gnomAD rs771596018, REVEL 0.10, CADD 18.50
- P169S (p.Pro169Ser), rs139951597, ClinGen CA4368622, ClinVar RCV004241016, ESP rs139951597, REVEL 0.04, CADD 11.20, Uncertain significance, not specified
- V170I (p.Val170Ile), gnomAD rs1280940118, REVEL 0.02, CADD 0.00
- K173R (p.Lys173Arg), ExAC rs764560819, TOPMed rs764560819, gnomAD rs764560819, REVEL 0.48, CADD 25.10
- D174G (p.Asp174Gly), 1000Genomes rs540181281, ExAC rs540181281, gnomAD rs540181281, REVEL 0.26, CADD 19.60
- D174H (p.Asp174His), NCI-TCGA TCGA novel, REVEL 0.22, CADD 16.70, Variant assessed as somatic; moderate impact.
- I175S (p.Ile175Ser), Ensembl rs1562995399
- Y179* (p.Tyr179Ter), ExAC rs748940694, TOPMed rs748940694, gnomAD rs748940694
- Y179C (p.Tyr179Cys), NCI-TCGA Cosmic COSV9976, Variant assessed as somatic; moderate impact.
- Y179F (p.Tyr179Phe), TOPMed rs1554420345, REVEL 0.34, CADD 23.70
- S180I (p.Ser180Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D182N (p.Asp182Asn), TOPMed rs1584446515
- V183G (p.Val183Gly), ExAC rs777252753, TOPMed rs777252753, gnomAD rs777252753, REVEL 0.85, CADD 26.10
- T185I (p.Thr185Ile), ExAC rs770303746, gnomAD rs770303746, REVEL 0.24, CADD 23.60
- G186A (p.Gly186Ala), rs962504304, NCI-TCGA Cosmic COSV5611, TOPMed rs962504304, gnomAD rs962504304, REVEL 0.11, CADD 16.30, Variant assessed as somatic; moderate impact.
- T187I (p.Thr187Ile), gnomAD rs1450180572, REVEL 0.40, CADD 25.30
- S188* (p.Ser188Ter), NCI-TCGA TCGA novel, CADD 35.00, Variant assessed as somatic; high impact.
- S188T (p.Ser188Thr), ESP rs202148429, ExAC rs202148429, TOPMed rs202148429, gnomAD rs202148429, REVEL 0.17, CADD 18.20
- F189L (p.Phe189Leu), ExAC rs781765557
Public CYP3A5 analysis runs
- CYP3A5 analysis run — CYP3A5 (785 variants) — completed 2026-08-10